Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis.

[1]  N. Harpaz,et al.  p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. , 1993, Gastroenterology.

[2]  L. Castagnetta,et al.  Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. , 1993, Cancer research.

[3]  Leland Hartwell,et al.  Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells , 1992, Cell.

[4]  M. Kimmey,et al.  DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. , 1992, Gastroenterology.

[5]  P. Rabinovitch,et al.  Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. , 1992, Gastroenterology.

[6]  R. Metcalf,et al.  p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. , 1992, Cancer research.

[7]  U. Pastorino,et al.  Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. , 1992, Cancer research.

[8]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[9]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression , 1992 .

[10]  B. Vogelstein,et al.  The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. , 1992, Gastroenterology.

[11]  B. Vogelstein,et al.  Clonal origin of bladder cancer. , 1992, The New England journal of medicine.

[12]  R. Metcalf,et al.  Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners , 1992, The Lancet.

[13]  D. Neal,et al.  c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder , 1992, The Lancet.

[14]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[15]  Patricia L. Blount,et al.  Distribution of aneuploid cell populations in ulcerative colitis with dysplasia or cancer. , 1991, Gastroenterology.

[16]  P. Rabinovitch,et al.  Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. , 1991, Cancer communications.

[17]  J. Milner,et al.  Tumor suppressor p53: analysis of wild-type and mutant p53 complexes , 1991, Molecular and cellular biology.

[18]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[19]  R. Riddell.  Dysplasia in Ulcerative Colitis , 1990 .

[20]  M. Leppert,et al.  Allelic Loss in Colorectal Carcinoma , 1989 .

[21]  G. Salzman.  New Technologies in Cytometry , 1989 .

[22]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[23]  I. Herskowitz.  Functional inactivation of genes by dominant negative mutations , 1987, Nature.

[24]  P. Nowell.  Mechanisms of tumor progression. , 1986, Cancer research.

[25]  D. Ransohoff,et al.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. , 1983, Human pathology.

[26]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[27]  J. Kirsner,et al.  Carcinoma of the colon in ulcerative colitis , 1964, Cancer.

[28]  J. Kirsner,et al.  Carcinoma and ulcerative colitis, a clinical-pathologic study. II. Statistical analysis. , 1958, Gastroenterology.

[29]  J. Kirsner,et al.  Carcinoma and ulcerative colitis, a clinical-pathologic study. I. Cancer deaths. , 1958, Gastroenterology.